<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03434470</url>
  </required_header>
  <id_info>
    <org_study_id>2016/1902</org_study_id>
    <nct_id>NCT03434470</nct_id>
  </id_info>
  <brief_title>Liver Elastography in Patients Undergoing Treatment for Hepatitis C</brief_title>
  <official_title>Liver Elastography in Patients Undergoing Treatment for Hepatitis C - a Longitudinal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the guidelines for treating hepatitis C livers stiffness (LS) measurement is
      equivalent to liver biopsy to prove grade-2 fibrosis or more by Metavir-score. Also flares of
      inflammation in other viral hepatitis (B) have been reported to increase the elastography
      measurements. There are very few reports so far on longitudinal data in a treatment cohort.
      In this study investigators will follow patients who undergo active treatment for hepatitis C
      virus (HCV). Investigators will collect longitudinal data of liver elastography and compare
      this to the current status of liver inflammation by blood samples. This may be important in
      order to know if transcutaneous US with elastography can be used as a tool to monitor active
      inflammation in liver disease and to quantify how much the inflammatory component contribute
      to LS and finally if it is possible to reverse not only inflammation but also liver fibrosis
      by treating viral hepatitis. Our aim is to assess shear wave elastography (SWE) and
      investigate if the method can be used, not only to define the indication for treatment
      through LS measurements, but also if LS due to inflammation and fibrosis may be reversible in
      treated patients. To investigate what role frequency of measurement obtains in follow up of
      patients with HCV play.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Elastography</measure>
    <time_frame>Baseline</time_frame>
    <description>Obtained liver stiffness measurements (kPa) at baseline of participants receiving antiviral treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient record</measure>
    <time_frame>Baseline</time_frame>
    <description>weight and height will be combined to report BMI in kg/m^2 at baseline of participants receiving antiviral treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemical analyses</measure>
    <time_frame>Baseline</time_frame>
    <description>Transaminases; aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT). Marker panels of liver fibrosis including AST to Platelet Ratio Index (APRI) and Fibrosis-4 index (FIB-4)will be calculated, at baseline of participants receiving antiviral treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B-mode evaluation of the liver</measure>
    <time_frame>Baseline</time_frame>
    <description>Evaluation of Liver angle (acute/blunt), Steatosis (yes/no), Liver capsule (regular/irregular), Liver parenchyma (normal/coarse) at baseline of participants receiving antiviral treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elastography</measure>
    <time_frame>3 months</time_frame>
    <description>Obtained liver stiffness measurements (kPa) after end treatment (EOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elastography</measure>
    <time_frame>6 months</time_frame>
    <description>Obtained liver stiffness measurements (kPa), 3 months after end of treatment (EOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elastography</measure>
    <time_frame>12 months</time_frame>
    <description>Obtained liver stiffness measurements (kPa), 1 year after EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-mode evaluation of the liver</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation of Liver angle (acute/blunt), Steatosis (yes/no), Liver capsule (regular/irregular), Liver parenchyma (normal/coarse) at at end of treatment (EOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-mode evaluation of the liver</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of Liver angle (acute/blunt), Steatosis (yes/no), Liver capsule (regular/irregular), Liver parenchyma (normal/coarse), 3 months after end treatment (EOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-mode evaluation of the liver</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of Liver angle (acute/blunt), Steatosis (yes/no), Liver capsule (regular/irregular), Liver parenchyma (normal/coarse), 1 year after EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient record</measure>
    <time_frame>3 months</time_frame>
    <description>weight and height will be combined to report BMI in kg/m^2 at end of treatment (EOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient record</measure>
    <time_frame>6 months</time_frame>
    <description>weight and height will be combined to report BMI in kg/m^2, 3 months after end treatment (EOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient record</measure>
    <time_frame>12 months</time_frame>
    <description>weight and height will be combined to report BMI in kg/m^2, 1 year after EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical analyses</measure>
    <time_frame>3 months</time_frame>
    <description>Transaminases; aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT). Marker panels of liver fibrosis including APRI and FIB-4 index will be calculated, at end of treatment (EOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical analyses</measure>
    <time_frame>6 months</time_frame>
    <description>Transaminases; aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT). Marker panels of liver fibrosis including APRI and FIB-4 index will be calculated, 3 months after EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical analyses</measure>
    <time_frame>12 months</time_frame>
    <description>Transaminases; aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT). Marker panels of liver fibrosis including APRI and FIB-4 index will be calculated, 1 year after EOT.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatitis C Virus Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be HCV patients (n= 50), who will be invited to join the study
        consecutively as they have indication to start medical antiviral treatment for 8-, 12-, or
        16 week, according to the genotype (1,2,3,4) and fibrosis stage.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with HCV

          -  HCV RNA positive

          -  Approved for HCV treatment

        Exclusion Criteria:

          -  Excessive alcohol use

          -  Pregnancy

          -  information of other cause of chronic liver disease (autoimmune hepatitis (AIH),
             primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC),
             Alpha-1-antitrypsin deficiency).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anesa Mulabecirovic</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bergen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anesa Mulabecirovic, MD</last_name>
    <phone>004793888212</phone>
    <email>anesa.mulabecirovic@uib.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roald Havre</last_name>
    <phone>004790842938</phone>
    <email>roald.flesland.havre@helse-bergen.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Bergen, Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <state>Hordaland</state>
        <zip>5057</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anesa Mulabecirovic, MD</last_name>
      <email>anesa.mulabecirovic@uib.no</email>
    </contact>
    <contact_backup>
      <last_name>Roald Havre, MD,PhD</last_name>
      <email>roald.flesland.havre@helse-bergen.no</email>
    </contact_backup>
    <investigator>
      <last_name>Anesa Mulabecirovic, MD, PhD-Cand</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Rafael Leiva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ultrasound</keyword>
  <keyword>Shear wave elastography</keyword>
  <keyword>SWE</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

